Towards a novel molecular classification of IBD

Area of Science:

• Gastroenterology
• Genetics
• Molecular Biology

Background:

• Current Inflammatory Bowel Disease (IBD) classification relies on clinical factors like age, disease location, and extent.
• The Montreal classification, while useful, was deemed insufficient for molecular reclassification in 2005.
• Advances in genetic research have identified over 100 IBD-associated genes and antimicrobial peptides.

Purpose of the Study:

• To explore the potential of molecular markers, particularly genetic variants, for classifying IBD patients.
• To assess the utility of genetic markers in disease stratification and predicting prognosis and therapy outcomes.
• To investigate the relationship between genetic-based subgroups and existing clinical subphenotypes.

Main Methods:

• Analysis of genetic variants in Crohn's disease (CD) patients to identify distinct clusters.
• Comparison of genetic-based patient clusters with healthy individuals.
• Evaluation of the correlation between genetic subgroups and established clinical subphenotypes.

Main Results:

• Genetic variants successfully classified CD patients into distinct clusters, differing from healthy populations.
• A poor correlation was observed between genetically defined subgroups and current clinical subphenotypes.
• Molecular markers show promise for disease stratification and predicting prognosis and treatment response.

Conclusions:

• Genetic factors provide a more robust basis for risk stratification in IBD.
• Molecular markers may elucidate pathogenic mechanisms and explain variations in disease behavior.
• Further development of tools to score disease progression is needed to fully explore the predictive value of molecular markers.